79 related articles for article (PubMed ID: 22777139)
21. Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice.
Hadland SE; Knight JR; Harris SK
J Dev Behav Pediatr; 2015; 36(2):115-23. PubMed ID: 25650954
[TBL] [Abstract][Full Text] [Related]
22. A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway.
Miyamoto J; Mizukure T; Park SB; Kishino S; Kimura I; Hirano K; Bergamo P; Rossi M; Suzuki T; Arita M; Ogawa J; Tanabe S
J Biol Chem; 2015 Jan; 290(5):2902-18. PubMed ID: 25505251
[TBL] [Abstract][Full Text] [Related]
23. Neuroinflammation as a possible link between cannabinoids and addiction.
Rodrigues LC; Gobira PH; de Oliveira AC; Pelição R; Teixeira AL; Moreira FA; Campos AC
Acta Neuropsychiatr; 2014 Dec; 26(6):334-46. PubMed ID: 25455257
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors.
Fichna J; Bawa M; Thakur GA; Tichkule R; Makriyannis A; McCafferty DM; Sharkey KA; Storr M
PLoS One; 2014; 9(10):e109115. PubMed ID: 25275313
[TBL] [Abstract][Full Text] [Related]
25. Activity of anandamide (AEA) metabolic enzymes in rat placental bed.
Fonseca BM; Battista N; Correia-da-Silva G; Rapino C; Maccarrone M; Teixeira NA
Reprod Toxicol; 2014 Nov; 49():74-7. PubMed ID: 25088244
[TBL] [Abstract][Full Text] [Related]
26. Cannabis for inflammatory bowel disease.
Naftali T; Mechulam R; Lev LB; Konikoff FM
Dig Dis; 2014; 32(4):468-74. PubMed ID: 24969296
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity.
Kim J; Watkins BA
J Nutr Biochem; 2014 Aug; 25(8):815-23. PubMed ID: 24854955
[TBL] [Abstract][Full Text] [Related]
28. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Wilhelmsen K; Khakpour S; Tran A; Sheehan K; Schumacher M; Xu F; Hellman J
J Biol Chem; 2014 May; 289(19):13079-100. PubMed ID: 24644287
[TBL] [Abstract][Full Text] [Related]
29. Endocannabinoids as biomarkers of human reproduction.
Rapino C; Battista N; Bari M; Maccarrone M
Hum Reprod Update; 2014; 20(4):501-16. PubMed ID: 24516083
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.
Sałaga M; Sobczak M; Fichna J
Eur J Pharm Sci; 2014 Feb; 52():173-9. PubMed ID: 24275607
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of vaginal adelmidrol for treating pelvic visceral discomforts and anxiety: a prospective observational study.
Indraccolo U; Scutiero G; Matteo M; Greco P
Minerva Ginecol; 2013 Aug; 65(4):465-70. PubMed ID: 24051946
[TBL] [Abstract][Full Text] [Related]
32. Endocannabinoid receptor deficiency affects maternal care and alters the dam's hippocampal oxytocin receptor and brain-derived neurotrophic factor expression.
Schechter M; Weller A; Pittel Z; Gross M; Zimmer A; Pinhasov A
J Neuroendocrinol; 2013 Oct; 25(10):898-909. PubMed ID: 23895426
[TBL] [Abstract][Full Text] [Related]
33. Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice.
Nakajima J; Nakae D; Yasukawa K
J Pharm Pharmacol; 2013 Aug; 65(8):1223-30. PubMed ID: 23837590
[TBL] [Abstract][Full Text] [Related]
34. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects.
Muguruza C; Lehtonen M; Aaltonen N; Morentin B; Meana JJ; Callado LF
Schizophr Res; 2013 Aug; 148(1-3):145-50. PubMed ID: 23800614
[TBL] [Abstract][Full Text] [Related]
35. New insights in mast cell modulation by palmitoylethanolamide.
De Filippis D; Negro L; Vaia M; Cinelli MP; Iuvone T
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):78-83. PubMed ID: 23394523
[TBL] [Abstract][Full Text] [Related]
36. The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.
Zogopoulos P; Vasileiou I; Patsouris E; Theocharis S
J Appl Toxicol; 2013 Apr; 33(4):246-64. PubMed ID: 23296873
[TBL] [Abstract][Full Text] [Related]
37. Behavioral responses to acute and sub-chronic administration of the synthetic cannabinoid JWH-018 in adult mice prenatally exposed to corticosterone.
Macrì S; Lanuzza L; Merola G; Ceci C; Gentili S; Valli A; Macchia T; Laviola G
Neurotox Res; 2013 Jul; 24(1):15-28. PubMed ID: 23296549
[TBL] [Abstract][Full Text] [Related]
38. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.
Alhouayek M; Muccioli GG
Trends Mol Med; 2012 Oct; 18(10):615-25. PubMed ID: 22917662
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoids in Periodontology: Where Are We Now?
Carmona Rendón Y; Garzón HS; Bueno-Silva B; Arce RM; Suárez LJ
Antibiotics (Basel); 2023 Nov; 12(12):. PubMed ID: 38136721
[TBL] [Abstract][Full Text] [Related]
40. Anandamide Attenuates Neurobehavioral Deficits and EEG Irregularities in the Chronic Sleep Deprivation Rats: The Role of Oxidative Stress and Neuroinflammation.
Belali R; Mard SA; Khoshnam SE; Bavarsad K; Sarkaki A; Farbood Y
Neurochem Res; 2024 Jun; 49(6):1541-1555. PubMed ID: 37966567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
